Following breakthrough results, we’re bringing longevity medicine to human trials.
We’ve raised a $435M Series C led by @foundersfund to make it happen.
Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.
Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients.
Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine.
Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine.
Read the full announcement here: https://t.co/TtXk3xqA84
I'm excited to see Thrive Holdings at the frontier of applying AI to the real economy — will be one of the most important problems of the next decade.
I'm excited to play my part at Renovus Capital.
We are excited to announce a strategic partnership between OpenAI and Thrive Holdings. Through our partnership, OpenAI will become an equity owner in Holdings, and collectively we will set out to deliver frontier technology for our customers.
For decades, technology has transformed the world’s largest industries from the outside-in. We believe the AI paradigm will be different in that some of the most profound transformations will now occur from the inside-out. We view the businesses that we own and operate as the right reward system to build, test, and improve industry-specific products and models.
The partnership will bring together a unique, cross-functional team, comprising OpenAI’s leading research and applied AI teams working alongside engineers, operators, and industry experts at Holdings to deeply integrate AI into the businesses that we own and operate. Our long-term orientation to transforming companies is possible because our time horizon at Holdings is forever.
By training the most advanced models for specific tasks within our businesses, guided by both company-specific data and expert feedback, we believe we can continuously improve model capabilities and ultimately establish AI as an integral driver of long-term enterprise value.
//
https://t.co/4NO7HkwffD
Had a trippy experience.
A VC walked me through his thesis for a fast-growing startup. I fed the detail into our experimental AI-analyst-in-a-spreadsheet… it nailed the valuation he bid, then built a full model I could tweak.
Today we’re opening it up: Introducing Ramp Sheets